Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...
-
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May...
-
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and...
-
CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12,...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...
-
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026Consistent, convergent improvements...
-
Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of...
-
FOMBONI, Comoros, May 12, 2026 (GLOBE NEWSWIRE) -- FX Junction has announced the release of a new research report examining the increasing influence of social media on stock market dynamics and...
-
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the...
-
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through...